Stephen M. Nicolai

Representative experience

Represented a clinical-stage pharmaceutical company in its US$80m initial public offering of common stock through a syndicate of underwriters led by Jefferies and Piper Jaffray.*

Represented a clinical-stage biopharmaceutical company in its US$40m at-the-market equity program led by Cowen and Company.*

Represented a clinical-stage biopharmaceutical company in a US$225m public offering of common stock through a syndicate of underwriters led by J.P. Morgan and Goldman Sachs.*

Regularly advises public companies on a range of corporate governance and securities matters, including fiduciary duties, periodic reports, Section 16 compliance, annual meetings and proxy statements.

Represented a specialty pharmaceutical company in its US$138m IPO of common stock through a syndicate of underwriters led by Jefferies and Piper Jaffray.

Represented OptiNose, Inc. in its US$120m follow-on public offering of common stock through a syndicate of underwriters led by Jefferies and Piper Jaffray.

Represented EyePoint Pharmaceuticals, Inc. in its acquisition of Icon Bioscience, Inc. and accompanying US$60m equity financing with a group of third party investors.

Represented a clinical-stage biotechnology company in its US$80m synthetic royalty financing transaction.

Served as internal legal counsel to the interventional vascular unit of a global health care company.

Represented a clinical-stage oncology company in its reverse merger into a Nasdaq-listed public company.

Represented several life companies in at-the-market equity offerings led by Jefferies, Cowen and Company, Cantor Fitzgerald, and B. Riley FBR.